Ayşe ULUSOY
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayşe ULUSOY has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Akif Asdemir
Department of Psychiatry Erciyes University Faculty of Medicine Kayseri Turkey
1 shared publication - Büşra Sultan Sevindik
Department of Psychiatry Erciyes University Faculty of Medicine Kayseri Turkey
1 shared publication - Ertuğrul Eşel
ERCİYES ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Eser Kilic
Department of Biochemistry, School of Medicine, Erciyes University
1 shared publication - Esra Kısacık
Ankara Bilim Üniversitesi
1 shared publication - Nurten Dikmen
Çukurova University
1 shared publication
Latest Publications
- 18 June 2026
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 41 (4) , e70052
Serum Galectin‐1 and Galectin‐3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder
Objective: Neuroinflammation is increasingly recognized as a key mechanism in the pathophysiology of Major Depressive Disorder (MDD). Galectin‐1 and Galectin‐3, β ‐galactoside‐binding lectins involved in immune regulation and neuroprotection, may serve as biomarkers linking inflammation to cognitive dysfunction. However, no previous study has simultaneously examined serum levels of these galectins alongside detailed cognitive assessments in MDD. This study aimed to determine whether Galectin‐1 and Galectin‐3 are altered in MDD and to explore their association with disease severity and cognitive performance. Method: Forty patients with MDD and 40 matched healthy controls were assessed. Depressive and anxiety symptoms were measured using the Hamilton Depression (HAM‐D) and Anxiety (HAM‐A) Rating Scales. Cognitive performance was evaluated with the Rey Auditory Verbal Learning Test, Go/No‐Go Test, and Stroop Test. Serum Galectin‐1, Galectin‐3, Glomerular Filtration Rate (GFR), and C‐reactive protein (CRP) levels were determined. Results: Serum Galectin‐1 and Galectin‐3 levels were significantly lower in the MDD group compared to controls ( p < 0.05). Galectin‐1 levels showed a negative correlation with HAM‐D and HAM‐A scores, indicating an inverse association with symptom severity (i.e., lower Galectin‐1 levels were associated with higher symptom severity). Patients exhibited impaired verbal learning, while no significant group differences were found in Go/No‐Go or Stroop performance. Galectin levels did not correlate with any cognitive test scores. Conclusion: Reduced Galectin‐1 and Galectin‐3 levels in MDD support their involvement in neuroinflammatory mechanisms. The inverse association between Galectin‐1 and symptom severity suggests that Galectin‐1 may be associated with symptom severity; however, the direction of this relationship remains unclear. The lack of associations with cognitive performance implies that cognitive deficits in MDD may be mediated by other immunometabolic pathways. These findings highlight galectins as promising but complex biomarkers, warranting further investigation in larger and longitudinal studies.
- 18 June 2026
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 41 (4) , e70052
Serum Galectin‐1 and Galectin‐3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder
Objective: Neuroinflammation is increasingly recognized as a key mechanism in the pathophysiology of Major Depressive Disorder (MDD). Galectin‐1 and Galectin‐3, β ‐galactoside‐binding lectins involved in immune regulation and neuroprotection, may serve as biomarkers linking inflammation to cognitive dysfunction. However, no previous study has simultaneously examined serum levels of these galectins alongside detailed cognitive assessments in MDD. This study aimed to determine whether Galectin‐1 and Galectin‐3 are altered in MDD and to explore their association with disease severity and cognitive performance. Method: Forty patients with MDD and 40 matched healthy controls were assessed. Depressive and anxiety symptoms were measured using the Hamilton Depression (HAM‐D) and Anxiety (HAM‐A) Rating Scales. Cognitive performance was evaluated with the Rey Auditory Verbal Learning Test, Go/No‐Go Test, and Stroop Test. Serum Galectin‐1, Galectin‐3, Glomerular Filtration Rate (GFR), and C‐reactive protein (CRP) levels were determined. Results: Serum Galectin‐1 and Galectin‐3 levels were significantly lower in the MDD group compared to controls ( p < 0.05). Galectin‐1 levels showed a negative correlation with HAM‐D and HAM‐A scores, indicating an inverse association with symptom severity (i.e., lower Galectin‐1 levels were associated with higher symptom severity). Patients exhibited impaired verbal learning, while no significant group differences were found in Go/No‐Go or Stroop performance. Galectin levels did not correlate with any cognitive test scores. Conclusion: Reduced Galectin‐1 and Galectin‐3 levels in MDD support their involvement in neuroinflammatory mechanisms. The inverse association between Galectin‐1 and symptom severity suggests that Galectin‐1 may be associated with symptom severity; however, the direction of this relationship remains unclear. The lack of associations with cognitive performance implies that cognitive deficits in MDD may be mediated by other immunometabolic pathways. These findings highlight galectins as promising but complex biomarkers, warranting further investigation in larger and longitudinal studies.
- Open Access
- 30 June 2020
- Published by Archives Medical Review Journal in Arşiv Kaynak Tarama Dergisi
- Vol. 29 (2) , 129-137
Hidrojellerin Tıpta Uygulamaları
Hidrojeller “Smart (akıllı)” yapılar olarak tanımlanan ilaç taşınım sistemleri, enjekte edilebilen polimer sistemleri, doku mühendisliği ve hücre enkapsülasyonu gibi tıpta yaygın olarak kullanılan polimerlerdir. Hidrojeller suyu yapılarında tutabilme özellikleri, yumuşak ve esnek yapıda olmaları ile canlı dokulara büyük benzerlik göstermektedirler. Toksisitesi olmayan, biyolojik olarak parçalanan ve biyolojik uyum gösterebilen yapıları sebebiyle hidrojellerin biyomalzeme olarak kullanılması giderek güvenli hale gelmektedir. Aynı zamanda hidrojellerin kontrollü serbest bırakma mekanizması, ilacın salınım hızını düzenleyen geleneksel dozaj yöntemleri karşısında birçok avantaj sağlamaktadır. Bu derlemede genel olarak yara örtüsünde, yanık, anevrizma tedavilerinde, kemik rejenerasyonunda, kardiyak doku onarım ve rejenerasyonunda, kontrollü ilaç salınımında, kontakt lenslerde, glokom tedavisinde kullanılan ve biyolojik araştırmaları devam etmekte olan hidrojellerden bahsedilmektedir.
- 30 June 2020
- Published by Archives Medical Review Journal in Arşiv Kaynak Tarama Dergisi
- Vol. 29 (2) , 129-137
Open AccessHidrojellerin Tıpta Uygulamaları
Hidrojeller “Smart (akıllı)” yapılar olarak tanımlanan ilaç taşınım sistemleri, enjekte edilebilen polimer sistemleri, doku mühendisliği ve hücre enkapsülasyonu gibi tıpta yaygın olarak kullanılan polimerlerdir. Hidrojeller suyu yapılarında tutabilme özellikleri, yumuşak ve esnek yapıda olmaları ile canlı dokulara büyük benzerlik göstermektedirler. Toksisitesi olmayan, biyolojik olarak parçalanan ve biyolojik uyum gösterebilen yapıları sebebiyle hidrojellerin biyomalzeme olarak kullanılması giderek güvenli hale gelmektedir. Aynı zamanda hidrojellerin kontrollü serbest bırakma mekanizması, ilacın salınım hızını düzenleyen geleneksel dozaj yöntemleri karşısında birçok avantaj sağlamaktadır. Bu derlemede genel olarak yara örtüsünde, yanık, anevrizma tedavilerinde, kemik rejenerasyonunda, kardiyak doku onarım ve rejenerasyonunda, kontrollü ilaç salınımında, kontakt lenslerde, glokom tedavisinde kullanılan ve biyolojik araştırmaları devam etmekte olan hidrojellerden bahsedilmektedir.